肾移植后慢性髓性白血病患者他克莫司与尼罗替尼之间的药物相互作用
Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant.
作者信息
Onaka Takashi, Takahashi Naoto, Miura Masatomo, Yonezawa Akihito
机构信息
Department of Hematology Kokura Memorial Hospital Kitakyushu Japan.
Department of Hematology, Nephrology, and Rheumatology Akita University Graduate School of Medicine Akita Japan.
出版信息
Clin Case Rep. 2017 Mar 17;5(5):605-607. doi: 10.1002/ccr3.900. eCollection 2017 May.
Nilotinib, a BCR-ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib-treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib.
尼罗替尼是一种BCR-ABL酪氨酸激酶抑制剂，是已知的CYP3A4抑制剂，可增加由CYP3A4代谢的药物浓度。由于其与尼罗替尼的相互作用，移植后接受尼罗替尼治疗的患者使用的免疫抑制药物应在仔细的药代动力学监测下给药。
Zotero 插件